This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.

The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

The present disclosure relates to a composition containing a Paeoniae radix extract as an active ingredient. The composition may alleviate inappetence, weight loss, muscle loss and fatigue and inhibit hematopoietic toxicity. Thus, the composition may be effectively used for the prevention, alleviation or treatment of cachexia and muscle loss.

The present disclosure relates to a composition containing a Paeoniae radix extract as an active ingredient. The composition may alleviate inappetence, weight loss, muscle loss and fatigue and inhibit hematopoietic toxicity. Thus, the composition may be effectively used for the prevention, alleviation or treatment of cachexia and muscle loss.

Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.

Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.

In certain aspects, the present invention provides novel ActRIIB variants (in a homomultimeric or heteromultimeric form), as well as compositions and methods for using those variants to treat an indication associated with undesired activity of one or more TGFβ-superfamily ligands. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

The present application relates to compositions comprising selenium (e.g., selenium enriched yeast) and methods of using the same to treat and inhibit obesity, diabetes and related conditions. In particular, the present application provides compositions comprising selenium enriched yeast (e.g., selenium enriched yeast comprising 2% or less inorganic selenium), and methods of using the same to enhance mitochondrial activity and function (e.g., in skeletal muscle and liver) in a subject (e.g., as a therapeutic and/or prophylactic treatment for diabetes, obesity and related conditions).